Tamoxifen or third‐generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0 M0, or stage IB ‐ III hormone receptor‐positive breast cancer. This evidence concerns the gene NR4A1 and breast carcinoma.